Design, Synthesis and Biological Evaluation of Novel Inhibitors of InhA from Mycobacterium tuberculosisTools Armstrong, Tom (2021) Design, Synthesis and Biological Evaluation of Novel Inhibitors of InhA from Mycobacterium tuberculosis. PhD thesis, University of Nottingham.
AbstractMulti-drug resistant tuberculosis (MDR-TB) represents a growing problem for global healthcare systems. The World Health Organisation reported 1.3 million deaths from tuberculosis in 2019, making the disease a leading cause of global mortality. In addition to this, there is an increasing spread of drug-resistant tuberculosis infections, with 390,000 new cases of MDR-TB recorded in 2019, these are infections resistant to Rifampicin and Isoniazid. Isoniazid is a key anti-TB drug and an inhibitor of InhA, a crucial enzyme in the cell wall biosynthesis pathway and identical in Mycobacterium tuberculosis and Mycobacterium bovis. Isoniazid is a prodrug which requires activation by the enzyme KatG, this active species then forms an adduct with the NAD+ cofactor which then binds to InhA and prevents substrate recognition. Mutations in KatG prevent this activation and confer INH-resistance. ‘Direct inhibitors’ of InhA are attractive as they would circumvent the main clinically observed resistance mechanisms.
Actions (Archive Staff Only)
|